Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases.
The aim of this study was to determine the efficacy of sagopilone (ZK-EPO), a novel epothilone, compared with other anticancer agents in orthotopic models of human primary and secondary brain tumors. Autoradiography and pharmacokinetic analyses were performed on rats and mice to determine passage across the blood-brain barrier and organ distribution of sagopilone. Mice bearing intracerebral human tumors (U373 or U87 glioblastoma, MDA-MB-435 melanoma, or patient-derived non-small-cell lung cancer [NSCLC]) were treated with sagopilone 5-10 mg/kg, paclitaxel 8-12.5 mg/kg (or temozolomide, 100 mg/kg) or control (vehicle only). Tumor volume was measured to assess antitumor activity. Sagopilone crossed the blood-brain barrier in both rat and mouse models, leading to therapeutically relevant concentrations in the brain with a long half-life. Sagopilone exhibited significant antitumor activity in both the U373 and U87 models of human glioblastoma, while paclitaxel showed a limited effect in the U373 model. Sagopilone significantly inhibited the growth of tumors from CNS metastasis models (MDA-MB-435 melanoma and patient-derived Lu7187 and Lu7466 NSCLC) implanted in the brains of nude mice, in contrast to paclitaxel or temozolomide. Sagopilone has free access to the brain. Sagopilone demonstrated significant antitumor activity in orthotopic models of both glioblastoma and CNS metastases compared with paclitaxel or temozolomide, underlining the value of further research evaluating sagopilone in the treatment of brain tumors. Sagopilone is currently being investigated in a broad phase II clinical trial program, including patients with glioblastoma, NSCLC, breast cancer, and melanoma.
Hoffmann
Jens
J
Bayer Schering Pharma AG, TRG Oncology, Berlin, Germany. jens.hoffmann@bayerhealthcare.com
Fichtner
Iduna
I
Lemm
Margit
M
Lienau
Philip
P
Hess-Stumpp
Holger
H
Rotgeri
Andrea
A
Hofmann
Birte
B
Klar
Ulrich
U
D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000493:pharmacokinetics / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000493:pharmacokinetics / Q000627:therapeutic use; D052160:Benzothiazoles / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001812:Blood-Brain Barrier; D001921:Brain / Q000378:metabolism*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D045744:Cell Line, Tumor; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000493:pharmacokinetics / Q000627:therapeutic use; D034261:Epothilones / Q000493:pharmacokinetics* / Q000627:therapeutic use; D005260:Female; D006207:Half-Life; D006801:Humans; D008297:Male; D051379:Mice; D008819:Mice, Nude; D017239:Paclitaxel / Q000493:pharmacokinetics / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D015996:Survival Rate; D000077204:Temozolomide; D023041:Xenograft Model Antitumor Assays
D018906:Antineoplastic Agents, Alkylating; D000972:Antineoplastic Agents, Phytogenic; D052160:Benzothiazoles; D034261:Epothilones; D003606:Dacarbazine; C530494:sagopilone; D017239:Paclitaxel; D000077204:Temozolomide
J Nucl Med. 2005 Nov;46(11):1866-71
16269601
J Neurooncol. 2003 Feb;61(3):203-7
12675312
Gynecol Oncol. 1994 Dec;55(3 Pt 1):456-8
7835788
Curr Probl Surg. 2004 Aug;41(8):665-741
15354117
Cancer. 1995 Jul 15;76(2):232-6
8625097
Int J Gynecol Cancer. 2006 May-Jun;16(3):994-9
16803475
Eur J Cancer. 2003 Jun;39(9):1271-6
12763216
Cancer Res. 2008 Jul 1;68(13):5301-8
18593931
Exp Biol Med (Maywood). 2005 Feb;230(2):118-27
15673560
Nat Clin Pract Neurol. 2006 Sep;2(9):494-503; quiz 1 p following 516
16932614
Clin Cancer Res. 2006 Oct 1;12(19):5770-6
17020983
Neurol Clin. 2003 Feb;21(1):107-40, viii
12690647
Cancer. 2002 Aug 1;95(3):605-12
12209754
Ann Oncol. 2001 Mar;12(3):353-6
11332148
Ann Oncol. 2006 Jun;17(6):952-6
16565212
J Anat. 2002 Jun;200(6):629-38
12162730
Angew Chem Int Ed Engl. 2006 Dec 4;45(47):7942-8
17006870
J Neurooncol. 2003 Nov;65(2):99-106
14686728
Chin Med J (Engl). 2007 Mar 20;120(6):458-62
17439736
Cancer. 2002 May 15;94(10):2698-705
12173339
Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1186-95
12654426
N Engl J Med. 2005 Mar 10;352(10):997-1003
15758010
Am J Pathol. 2005 Oct;167(4):913-20
16192626
J Neurosurg. 1998 Jan;88(1):11-20
9420067
J Neurooncol. 2005 Oct;75(1):5-14
16215811
J Clin Oncol. 1999 Sep;17(9):2762-71
10561351
Br J Cancer. 2004 Aug 16;91(4):639-43
15266327
J Clin Oncol. 2004 Jul 15;22(14):2865-72
15254054
Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6950-8
16203787